|
[1]
|
Day Baird, D., Dunson, D.B., Hill, M.C., Cousins, D. and Schectman, J.M. (2003) High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. American Journal of Obstetrics and Gynecology, 188, 100-107. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Vilos, G.A., Allaire, C., Laberge, P., Leyland, N., Vilos, A.G., Murji, A., et al. (2015) The Management of Uterine Leiomyomas. Journal of Obstetrics and Gynaecology Canada, 37, 157-178. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
National Institute for Health and Care Excellence (2007) Heavy Menstrual Bleeding. Clinical Guideline CG44. http://guidance.nice.org.uk/CG44
|
|
[4]
|
Spitz, I.M. (2009) Clinical Utility of Progesterone Receptor Modulators and Their Effect on the Endometrium. Current Opinion in Obstetrics & Gynecology, 21, 318-324. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Maruo, T. (2000) Effects of Progesterone on Uterine Leiomyoma Growth and Apoptosis. Steroids, 65, 585-592. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Donnez, J., Tatarchuk, T.F., Bouchard, P., Puscasiu, L., Zakharenko, N.F., Ivanova, T., et al. (2012) Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. New England Journal of Medicine, 366, 409-420. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Donnez, J., Tomaszewski, J., Vázquez, F., Bouchard, P., Lemieszczuk, B., Baró, F., et al. (2013) Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. Obstetrical & Gynecological Survey, 68, 99-100. [Google Scholar] [CrossRef]
|